Actively Recruiting
Plasma Biomarker in Amblyopia Patients
Led by Zhongshan Ophthalmic Center, Sun Yat-sen University · Updated on 2023-01-31
600
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.
CONDITIONS
Official Title
Plasma Biomarker in Amblyopia Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with amblyopia
- Aged between 3 and 12 years
- Able to tolerate amblyopia treatment
- Agree to participate in the study and attend follow-up visits every 3 months
You will not qualify if you...
- Previous treatment history for amblyopia
- Known pathological eye abnormalities causing reduced visual acuity
- History of psychiatric, visual, or neurological disorders
- Presence of eccentric fixation or abnormal retinal correspondence
- Attention disorder or learning disability preventing comprehension of test instructions or consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
J
Jinrong Li, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here